Posts

Tom Essaye Quoted in Unseen Opportunity on January 26, 2021

“The short squeeze/volatility we saw in heavily-shorted stocks such as GameStop and others yesterday only further confirms that, at least in the near term…” explained Tom Essaye, founder of The Sevens Report, in a note. Click here to read the full article.

Stimulus Winners and Losers

What’s in Today’s Report:

  • Stimulus Winners and Losers
  • Empire State Manufacturing Survey Takeaways

Stock futures are higher with global shares today as investors look ahead to the Fed following upbeat economic data o/n while a stimulus deal has still not been reached.

Economically, EU Flash Composite PMIs came in better than expected with the German Manufacturing and the French Services components both handily beating expectations, pointing to still healthy and resilient recovery.

Today, there are a few economic reports to watch in the U.S. session. In order of importance they are: Retail Sales (E: -0.3%), PMI Composite Flash (E: 57.4), Business Inventories (E: 0.6%), and Housing Market Index (E: 88.0).

After the morning data, focus will turn to the Fed with the FOMC Meeting Announcement at 2:00 p.m. ET, followed by Fed Chair Powell’s Press Conference at 2:30 p.m. ET.

With investors keenly watching the Fed for clues about the future or QE and ZIRP today, ongoing negotiations for a stimulus package on Capitol Hill will remain a key influence to watch as well, as a deal is largely priced in with the S&P trading just shy of record highs and any disappointment regarding the next round of coronavirus aid could result in a significant uptick in volatility.

Tom Essaye Quoted in CNBC on November 9, 2020

S&P 500 could hit 3,900, according to the Sevens Report

Amid news of a successful Covid-19 vaccine, the S&P 500 making a run to the 3,900 level is possible, according to editor of the Sevens Report, Tom Essaye. “It is materially bullish for stocks in the near term…” Essaye told clients. Click here to read the full article.

What the Vaccine News Means for Markets

What’s in Today’s Report:

  • Vaccine Playbook (Specific Sectors and ETFs)
  • What the Vaccine Means for Markets
  • Why Stocks Have Rallied (Four Reasons – Not Just the Election and Vaccine)
  • Weekly Market Preview:  How High Can Stocks Go?
  • Weekly Economic Cheat Sheet:  Jobless Claims the Key Number on Thursday

Futures have exploded to new all-time highs on positive vaccine results from Pfizer, combined with election uncertainty.

Pfizer just released results stating its COVID-19 vaccine is more than 90% effective in preventing COVID-19 infection among people who had not been previously infected.  That 90% is much higher than was expected.

Election clarity had stocks higher pre-vaccine news as Biden was projected to win the Presidency.

Today it’s all about momentum and as stocks should surge led by value, cyclicals and the “Get out and spend” sectors.

Tom Essaye Quoted in Axios on November 4, 2020

Stock investors may be in something of a “post-election fog” or a “drunken euphoria” about an apparent quick conclusion to the presidential race but may also be repricing expectations for economic growth, says Tom Essaye, director of Sevens Report Research. Click here to read the full article.

Tom Essaye Quoted in Barron’s on October 2, 2020

For now, though, all eyes are on Washington. “For the next several days reports of President Trump’s health will…” writes The Sevens Report’s Tom Essaye. Click here to read the full article.

FOMC Preview (What Makes It Dovish Enough?)

What’s in Today’s Report:

  • FOMC Preview (What Will Make It Dovish Enough for the Market?)
  • Why Did Stocks Rally on Monday?

Futures are moderately higher again following better than expected economic data overnight.

Chinese economic data was solid as August Retail Sales (0.5% vs. (E) 0.1%) and Industrial Production (5.6% vs. (E) 5.1%) both beat estimates.  In Europe, the German ZEW expectations index also beat estimates (77.4 vs. (E) 69.5).  Bottom line, the data implies the global economic recovery is still on going.

On the vaccine front, headlines were more mixed as the resumption of the AZN trial in the U.S. isn’t expected until the middle of this week, at the earliest.  But, markets still very much expect a vaccine to be approved by Election Day and distributed by year-end (and that remains a very optimistic assumption).

Today the looming Fed meeting (tomorrow) should keep the markets generally quiet, although we do get the September Empire Manufacturing Survey (E: 6.5), which is the first data point for September.  If it’s stronger than expected, that will further confirm the U.S. economy remains resilient despite no more stimulus, and that will help support the early rally in futures.

Tom Essaye Quoted in CNBC on September 2, 2020

“Let me be clear: The only reason we do not have a stimulus bill passed yet is because the economy and the markets are performing…” said Tom Essaye, founder of The Sevens Report. Click here to read the full article.

Tom Essaye Quoted in Forbes on August 13, 2020

Investors are still expecting another stimulus package will eventually get passed: “The market still wants, and very much expects, an actual stimulus bill to be signed…” according to Tom Essaye, editor of the Sevens Report. Click here to read the full article.

The Vaccine Playbook

What’s in Today’s Report:

  • The Vaccine Playbook

S&P 500 futures are approaching record highs this morning amid news that Russia has approved a COVID-19 vaccine while investors remain optimistic for a U.S. stimulus deal.

In a televised meeting, Russian President, Vladimir Putin, stated that Moscow’s Gamaleya Institute successfully developed a “safe and effective” coronavirus vaccine ready to move to a Phase 3 trial, sparking risk-on money flows.

Economically, both the German ZEW Survey and the NFIB Small Business Optimism Index largely met estimates and importantly did not alter the narrative that the broader global economic recovery remains underway.

Today, there is one economic report: PPI (E: 0.3%) and one Fed official is scheduled to speak: Daly (12:00 p.m. ET) but neither should move markets as investors will be keenly focused on the details surrounding the Russian coronavirus vaccine as well as any new progress towards a deal on the next U.S. stimulus bill.